P-SCN-Bn-DOTA

P-SCN-Bn-DOTA is a bifunctional chelating agent. p-SCN-Bn-DOTA can simultaneously chelate radionuclides and link monoclonal antibody for radioimmunoresearch of tumor[1][2].

Product Specifications

CAS Number

[127985-74-4]

Product Name Alternative

RP 29761,OPC-14857; DM-14857

UNSPSC

12352005

Hazard Statement

H301, H315, H319, H334, H335

Target

Others

Type

Reference compound

Related Pathways

Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/p-scn-bn-dota.html

Purity

99.78

Solubility

DMSO : 20.83 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(O)CN1C(CC2=CC=C(N=C=S)C=C2)CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1

Molecular Formula

C24H33N5O8S

Molecular Weight

551.61

Precautions

H301, H315, H319, H334, H335

References & Citations

[1]Vera DRB, et, al. Preclinical evaluation of (177) lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors. Cancer Biother Radiopharm. 2011 Jun;26 (3) :287-97.|[2]Giannini G, et, al. Synthesis and preliminary in vitro evaluation of DOTA-Tenatumomab conjugates for theranostic applications in tenascin expressing tumors. Bioorg Med Chem. 2019 Aug 1;27 (15) :3248-3253.